Company intelligence / Profile preview

Restored Vision

Tokyo, Tokyo-to, Japanrestored-vision.com ↗

Ownership: Private
Development stage: Commercial

Overview

Restore Vision has initiated a Phase 1/2 clinical trial for its lead candidate, RV‑001, the world’s first optogenetic "chimeric rhodopsin" gene therapy for retinitis pigmentosa. The first patient was dosed in February 2025. Early results indicate the starting dose is generally well tolerated in this open-label trial. The approach is gene agnostic and aims to restore vision by expanding light sensitivity to retinal interneurons via intravitreal injection of an AAV vector encoding chimeric rhodopsin

Therapeutic areas: Ophthalmology
Modalities: Gene therapyAAV based gene therapyOptogenetics-based therapyProtein (Chimeric Rhodopsin)
Industry: Biotech

Partnerships

Keio University School of Medicine (academic collaboration/research origin)

Beyond the preview

Go deeper on Restored Vision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Restored Vision.

Explore the full profile